A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity,
and pharmacokinetics of AMN107 in six groups of patients with one of the following
conditions:
Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1)
Group A - Imatinib failure only (arms 2, 3 and 4)
- imatinib-resistant or intolerant CML - Chronic Phase (CP)
- imatinib-resistant or intolerant CML - Accelerated Phase (AP)
- imatinib-resistant or intolerant CML - Blast Crisis (BC)
Group B - Imatinib and other TKI failure (arms 2, 3 and 4)
- imatinib-resistant or intolerant CML - Chronic Phase (CP)
- imatinib-resistant or intolerant CML - Accelerated Phase (AP)
- imatinib-resistant or intolerant CML - Blast Crisis (BC)
Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5)
Systemic mastocytosis (Sm) (arm 6)